Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more
Apollomics Inc. Class A Ordinary Shares (APLM) - Total Assets
Latest total assets as of September 2025: $11.12 Million USD
Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) holds total assets worth $11.12 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apollomics Inc. Class A Ordinary Shares - Total Assets Trend (2019–2024)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Apollomics Inc. Class A Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Apollomics Inc. Class A Ordinary Shares's total assets of $11.12 Million consist of 78.4% current assets and 21.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.6% |
| Accounts Receivable | $127.00K | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.74 Million | 13.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apollomics Inc. Class A Ordinary Shares's current assets represent 78.4% of total assets in 2024, a decrease from 95.4% in 2019.
- Cash Position: Cash and equivalents constituted 74.6% of total assets in 2024, up from 48.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 13.3% of total assets.
Apollomics Inc. Class A Ordinary Shares Competitors by Total Assets
Key competitors of Apollomics Inc. Class A Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Apollomics Inc. Class A Ordinary Shares - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Apollomics Inc. Class A Ordinary Shares generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Apollomics Inc. Class A Ordinary Shares is currently not profitable relative to its asset base.
Apollomics Inc. Class A Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.97 | 1.39 | 16.48 |
| Quick Ratio | 0.97 | 1.39 | 16.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-343.00K | $ 2.87 Million | $ 70.85 Million |
Apollomics Inc. Class A Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Apollomics Inc. Class A Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.12 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -76.4% |
| Total Assets | $13.10 Million |
| Market Capitalization | $10.57 Million USD |
Valuation Analysis
Near Book Valuation: The market values Apollomics Inc. Class A Ordinary Shares's assets close to their book value ( 0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Apollomics Inc. Class A Ordinary Shares's assets decreased by 76.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apollomics Inc. Class A Ordinary Shares (2019–2024)
The table below shows the annual total assets of Apollomics Inc. Class A Ordinary Shares from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.10 Million | -76.35% |
| 2023-12-31 | $55.39 Million | -27.58% |
| 2022-12-31 | $76.47 Million | -38.05% |
| 2021-12-31 | $123.44 Million | -27.36% |
| 2020-12-31 | $169.94 Million | +114.97% |
| 2019-12-31 | $79.05 Million | -- |